Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer

Intelligence artificielle : quel avenir en anatomie pathologique ?

(2019) Ryad Zemouri et al.   ANNALES DE PATHOLOGIE

Deep Learning in the Biomedical Applications: Recent and Future Status

(2019) Ryad Zemouri et al.   Applied Sciences-Basel

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Applying new Magee equations for predicting the Oncotype Dx recurrence score

(2018) Maher Sughayer et al.   Breast Cancer

OUP accepted manuscript

(2018)   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning

(2018) Isaac Kim et al.   EJSO

NCCN Guidelines Insights: Breast Cancer, Version 1.2017

(2017) William J. Gradishar et al.   Journal of the National Comprehensive Cancer Network

A survey on deep learning in medical image analysis

(2017) Geert Litjens et al.   MEDICAL IMAGE ANALYSIS

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2016) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score

(2016) Thaer Khoury et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) E. Senkus et al.   ANNALS OF ONCOLOGY

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study

(2015) B Yeo et al.   BRITISH JOURNAL OF CANCER

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score

(2015) Bradley M Turner et al.   MODERN PATHOLOGY

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

(2015) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival

(2015) Se Kyung Lee et al.   PLoS One

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

(2013) Molly E Klein et al.   MODERN PATHOLOGY

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information

(2013) Linda P Feeley et al.   MODERN PATHOLOGY

Distincttumor protein p53mutants in breast cancer subgroups

(2012) Anne Dumay et al.   INTERNATIONAL JOURNAL OF CANCER

Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?

(2011) K. H. Allison et al.   BREAST CANCER RESEARCH AND TREATMENT

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53

(2011) E K A Millar et al.   BRITISH JOURNAL OF CANCER

A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas

(2011) Geza Acs et al.   MODERN PATHOLOGY

A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer

(2010) Ping Tang et al.   CANCER INVESTIGATION

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

Histopathologic variables predict Oncotype DX™ Recurrence Score

(2008) Melina B Flanagan et al.   MODERN PATHOLOGY